Product Images Cabometyx

Cabometyx is a medication used to treat certain types of cancer. Each tablet contains 20 mg of cabozantinib and should be taken once a day on an empty stomach. The drug should be swallowed whole and not crushed. Cabometyx can be stored at 20°C to 25°C and made in Germany. This drug should be kept out of the reach of children. NDC 42388-024-26.*

Cabometyx tablets contain 20mg of cabozantinib and should be taken once daily on an empty stomach, either one hour before eating or two hours after eating. The tablets should be swallowed whole and should not be crushed. Cabometyx should be stored at room temperature between 20°C to 25°C. The medication should be kept out of reach of children. NDC number for Cabometyx Tablets is 42388-024-26. Cabometyx is manufactured for Exelis, Inc. in Canada.*

Each tablet contains 20mg of a medication called Cabometyx that is manufactured by Exelixis®. These tablets should be taken once a day, with an empty stomach. This is a professional sample and it is not for sale. The pack contains 15 Tablets. The storage temperature should be between 20°C to 25°C (68°F to 77°F), and these tablets should be kept away from children. The expiration date is MM/YYYY and the lot number is zzz27Z.*

Each Cabometyx tablet contains 40mg of cabozantinib (equivalent to 51mg of cabozantinib (S)-malate) and should be taken once per day on an empty stomach, at least 1 hour before or 2 hours after eating. The tablets should be swallowed whole and not crushed. Cabometyx should be stored at 20°C to 25°C (68°F to 77°F), with permitted excursions from 15°C to 30°C (59°F to 86°F). The drug should be kept out of the reach of children. The NDC number is 42388-025-26, and Cabometyx is available by prescription only.*

Each Cabometyx tablet contains 40mg of cabozantinib. This medication is taken once a day on an empty stomach. Cabometyx should not be taken with food. Store between 20°C to 25°C (68°F to 77°F). Do not crush the tablets. Cabometyx is manufactured for Exelis, Inc. and made in Canada. Keep away from children.*

Each tablet contains 40mg of cabozantinib. This is a professional sample that is not for sale to the public. The product has an NDC code of 42386.025.37. It is advised to take this medication once a day on an empty stomach. The package comes with 15 tablets. The storage temperature is between 20°C to 25°C and should be kept away from children's reach. The lot number is 22272 and the expiration date is stated on the package.*

Each tablet of Cabometyx contains 60 mg of cabozantinib. It is recommended to take the medication without food, at least 1 hour before or 2 hours after eating. The tablets should be swallowed whole and not crushed. Cabometyx must be stored at room temperature (20°C to 25°C) and kept out of the reach of children. The text also includes details such as the NDC number and manufacturer (EXELIXIS®).*

Cabometyx is a prescription medicine containing Cabozantinib (60mg per tablet), to be taken once a day on an empty stomach. It should be taken at least an hour before or two hours after eating. Cabometyx should be swallowed whole and not crushed. It should be stored at 20 to 25°C and excursions are allowed from 15 to 30°C. It is manufactured for Exelis, Inc. and should be kept out of the reach of children. NDC 42388-023-26.*

Each table contains Cabozrtib equivalent to 0.76 g of Cabozanind (5)-malate. It is a professional sample and not for sale. The drug is known as Cabometyx and utilized in the treatment of oncosach. Cabometyx should be taken in an empty stomach at least 1 hour before or 2 hours after eating. The drug should be swallowed whole and stored at a temperature between 20-25°C. It is important to keep the drug away from children. The Manufacturer is Exelixis and the Lot number and expiration date are 222777 and MM/YYYY respectively.*

The text seems to be a graph showing the comparison between the overall survival of patients treated with CABOMETYX and Everolimus. The graph appears to plot the months against the number at risk of the two treatments.*

This is a representation of the Probability of Progression-free Survival for two drugs, CABOMETYX and Sunitinib, over a period of 27 months. The graph shows the percentage of patients that are still alive without any progression of their illness. The X-axis shows the time in months, and the Y-axis shows the percentage of patients. The blue curve indicates the probability for CABOMETYX, and the orange curve Sunitinib. The numbers on the graph indicate the number of patients who are alive as the study progresses.*

This document seems to be a graph depicting the probability of progression-free survival over time for two different treatments (CABOMETVX + nivalumeb and aunitinb). The x-axis shows the duration in months and the y-axis shows the probability of survival. The graph also includes the number of subjects at risk over time for each treatment.*

This appears to be a survival graph that compares the efficacy of a drug called CABOMETYX versus a placebo. It seems to show the number at risk for each group over a period of 42 months, along with the number of patients who survived at each month milestone.*

This table provides information on the "Probability of Progression-Free Survival" for a drug called "CABOMETYX" versus a placebo. The table includes the number of individuals at risk for each treatment group, but without further context or information, it is not possible to draw any conclusions about the effectiveness of the drug.*

The text seems to be a table showing the "Number at risk" for a treatment called CABOMETYX and a placebo, and their "Probability of Progression-Free Survival". However, without additional information or context, it's difficult to provide further information or analysis.*